CallTower Expands Global In-Country Connectivity With Operator Connect for Microsoft Teams
CallTower Expands High-Quality Operator Connect to 27 Countries, Enhancing Seamless Global Communication for Enterprises.
SALT LAKE CITY, UT / ACCESSWIRE / November 13, 2024 / CallTower, a global leader in delivering cloud communication (unified communications, contact center, mobility, and collaboration) solutions, including Microsoft Teams, Webex by Cisco, and Zoom solutions, is excited to announce the significant expansion of its Operator Connect for Microsoft Teams service across the globe. CallTower has expanded its coverage to provide enterprise clients with high-quality, resilient voice solutions across 27 countries, further strengthening its ability to support seamless communication for global organizations. CallTower has expanded into LATAM and APAC building on their established presence in the US, Canada, and EMEA, further solidifying CallTower's commitment to enhancing global communications.
As of today, CallTower Operator Connect is available in the following locations: Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, Germany, France, Finland, Greece, Hungary, Ireland, Israel, Italy, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom, and United States. This expansion reflects CallTower's commitment to meeting the growing demands of global enterprises seeking reliable, fully integrated Teams calling solutions.
Operator Connect for Microsoft Teams offers an intuitive way for companies to add PSTN calling to Microsoft Teams while benefiting from CallTower's high-touch customer support and expert guidance. By using CallTower Operator Connect, clients gain access to a streamlined solution that bypasses the complexity of third-party providers, ensuring a simplified experience without compromising functionality or reliability.
"Expanding our Operator Connect service to cover more countries enhances our ability to support multinational clients with the connectivity they need in today's globalized business landscape," said William Rubio, CallTower's Chief Revenue Officer. "We aim to take Operator Connect for Microsoft Teams to the next level. We want to provide an unmatched, scalable solution that enables companies to enhance collaboration, drive productivity, and reach new heights in global communications."
In March of 2024, CallTower expanded its Operator Connect with its EMEA expansion.
Furthermore, CallTower delivers key Operator Connect business integrations that ensure an exceptional customer experience, including contact center, CRM integration, SMS texting, compliance recording, enhanced analytics, and Teams Mobile.
Transforming how we connect across the globe! Dive into the future of global communication with CallTower, where the forefront of innovation meets the vast expanse of connectivity. CallTower is revolutionizing communications through cutting-edge technology. CallTower delivers seamless MS Teams, Zoom, and Webex voice solutions elevated by the integration of AI technology, comprehensive contact center solutions, and one-click failover, marking a significant milestone in the communication landscape.
Since its establishment in 2002, CallTower has evolved into a global cloud-based, enterprise-class cloud communications (unified communications, contact center, and collaboration) solutions provider, catering to the needs of expanding businesses globally. CallTower offers and supports cutting-edge solutions such as Operator Connect for Microsoft® Teams, MS Teams Direct Routing, GCC High Teams Direct Routing, Microsoft® 365, Cisco® Webex Calling / UCM, Cisco® CCP, Zoom Phone, and Zoom (BYOB), and a range of contact center options, including Five9 for business customers.
For more information about CallTower and its award-winning services, please contact marketing@calltower.com.
Contact Information
Kade Herbert
Marketing Manager
kherbert@calltower.com
(702) 951-2449
Tonya Wheatfall
Marketing Coordinator
twheatfall@calltower.com
9406665906
SOURCE: CallTower, Inc.
View the original press release on newswire.com.
CallTower
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom